eNOS Rabbit pAb
- Known as:
- eNOS Rabbit pAb
- Catalog number:
- ASAKAP-NO021F
- Product Quantity:
- 200 µg
- Category:
- -
- Supplier:
- Other suppliers
- Gene target:
- eNOS Rabbit pAb
Related genes to: eNOS Rabbit pAb
- Gene:
- NOS3 NIH gene
- Name:
- nitric oxide synthase 3
- Previous symbol:
- -
- Synonyms:
- ECNOS, eNOS
- Chromosome:
- 7q36.1
- Locus Type:
- gene with protein product
- Date approved:
- 1993-08-23
- Date modifiied:
- 2016-10-05
Related products to: eNOS Rabbit pAb
guanine nucleotide binding protein alpha inhibiting activity polypeptide 1 (GNAI1) polyclonal antibody kinase suppressor of ras (KSR) polyclonal antibody(Alpha)_ 1 _ antitrypsin (A1AT) POLYCLONAL Rabbit anti_human(Alpha)_ Feto Protein (AFP) POLYCLONAL Rabbit anti_human(Alpha)_ Feto Protein (AFP) POLYCLONAL Rabbit anti_human(Alpha)_1_ antitrypsin (A1AT) POLYCLONAL Rabbit anti_human(Arg6,b_cyclohexyl_Ala8,D_Tic16,Arg17,Cys18)_Atrial Natriuretic Factor (6_18) amide (mouse, rabbit, rat) Salt _ Binding (Disulfide_bond) Synonym A71915 SumFormula C69H116N26O15S2(Arg6,b_cyclohexyl_Ala8,D_Tic16,Arg17,Cys18)_Atrial Natriuretic Factor (6_18) amide (mouse, rabbit, rat) Salt _ Binding (Disulfide_bond) Synonym A71915 SumFormula C69H116N26O15S2(Arg6,β-cyclohexyl-Ala8,D-Tic16,Arg17,Cys18)-Atrial Natriuretic Factor (6-18) amide (mouse, rabbit, rat)
A71915 98% C69H116N26O15S2 CAS:(Arg8)-Vasopressin - Diluted Antiserum for RIA, Host Rabbit(Arg8)-Vasopressin - Diluted Antiserum for RIA, Host: Rabbit(Arg8)-Vasopressin - Diluted Antiserum for RIA, Host: Rabbit(Arg8)-Vasopressin - EIA Kit (H - sr, pl), Host Rabbit, Extraction-free, CE-marked(Arg8)-Vasopressin - EIA Kit (H - sr, pl), Host RabbitExtraction-freeCE-marked(Arg8)-Vasopressin - EIA Kit (H - sr, pl), Host: Rabbit, Extraction-free, CE-marked Related articles to: eNOS Rabbit pAb
- Ulcerative colitis (UC) is marked by epithelial barrier damage and immune dysregulation, and current therapies often fail to achieve both effective inflammation control and durable immune restoration. Rexiao Kuining decoction (RXKND), derived from San Huang Xie Xin decoction recorded in Synopsis of Prescriptions of the Golden Chamber, has been used clinically for UC, but its mechanisms remain unclear. - Source: PubMed
Publication date: 2026/06/08
Xiao Si-NanCai TaoXia Jia-YiZhou LingCao Ruo-XiCao Bo - Rosavin, a characteristic component of Rhodiola rosea L., exhibits various pharmacological activities, including antioxidant and anti-inflammatory effects. However, its role in alcoholic fatty liver disease (AFLD) remains unclear. The aim of this study was to investigate the protective effects of Rosavin against AFLD and to elucidate its underlying molecular mechanisms. In this study, Rosavin (25 μM and 50 μM for in vitro; 100 and 200 mg/kg/d via oral gavage for 10 days in vivo) was found to significantly mitigate alcohol-induced hepatic lipid accumulation, enhance antioxidant capacity, and alleviate liver injury, demonstrating its protective effects against AFLD both in vitro and in vivo. Through network pharmacology and molecular docking, six potential targets of Rosavin in AFLD were identified: nitric oxide synthase 3 (NOS3), proto-oncogene tyrosine-protein kinase Src (SRC), peroxisome proliferator-activated receptor gamma (PPARG), mitogen-activated protein kinase 14 (MAPK14, also known as p38α), tumor necrosis factor alpha (TNFα), and insulin-like growth factor 1 (IGF-1). RT-qPCR and western blotting confirmed that Rosavin downregulates PPARG, TNFα, and IGF-1 expression and suppresses p38 phosphorylation. Rescue experiments further revealed that the suppressive effect of Rosavin on PPARG expression is reversed by the PPARG-specific agonist Mesalazine, which not only counteracts the protective effects of Rosavin but also reverses Rosavin-induced changes in MAPK14 and IGF-1 expression. In conclusion, Rosavin alleviates AFLD by downregulating PPARG and subsequently modulating the MAPK14 and IGF-1 signaling pathways. This study provides the first evidence that Rosavin protects against AFLD via PPARG, highlighting its potential as a therapeutic agent for AFLD treatment. - Source: PubMed
Publication date: 2026/06/09
Wang ShenCai JinhuiTang ZiqingChen ShurongChen HuikeTan YunjuanHuang RuiruiWu MinhuaWu YanxiaYe Xiaoxia - Hearing impairment is attributed to factors such as age, genetic predisposition, and environmental influences, among which environmental factors are considered modifiable. Among various environmental factors, the role of poor lifestyle habits is particularly critical, yet the specific mechanisms by which they contribute to hearing damage remain unclear. This study reveals that dysregulated hormone levels due to disrupted light exposure may significantly increase susceptibility to sensorineural hearing loss. In mice, circadian rhythm disruption was found to reduce melatonin and elevate serotonin levels in the inner ear, thereby increasing vulnerability to cisplatin-induced ototoxicity. In both in vivo and in vitro cisplatin-treatment models, we showed that combined treatment with melatonin protected hearing, reduced inner ear cell death, and preserved synaptic connections, whereas serotonin co-administration exacerbated the damage. Using small molecule-protein interaction prediction, we identified NOS3 as a potential target of both melatonin and serotonin, through which they appear to regulate the NO signaling pathway and influence hair cell ferroptosis. Finally, exogenous supplementation of NOS3 in cochlear tissues effectively mitigated cisplatin-induced hair cell damage, even under conditions of circadian rhythm disruption. These findings indicate that the melatonin/serotonin balance modulates susceptibility to sensorineural hearing loss via the NOS3-NO signaling pathway. - Source: PubMed
Qiu SiyuCai ShiyiXie RongLiu ChangHe Yingzi - Coronary heart disease (CHD) remains a major global health burden, and residual cardiovascular risk persists despite guideline-based therapies. Danggui Sini Granule (DSG), a granule formulation derived from the classical Danggui Sini Decoction, has been widely used clinically to improve cardiovascular circulation and alleviate ischemic symptoms; however, its gut-heart-axis-related mechanisms remain insufficiently defined. - Source: PubMed
Publication date: 2026/05/22
Tang HaipengSun ZhiliangWang ShanshanChen ZhiWang WenzhuWang YangGong JiyuXie XiaoyanGao Wenyi - Understanding of the possible vasoactive toxicities associated with platinum‑containing chemotherapeutic drugs for solid tumors remains limited. - Source: PubMed
Publication date: 2026/06/03
Chen YuzhuWang ChunhuaJiang PengChen YidaZhang TongmeiCai Shanshan